Kronos Bio, Inc. announced the appointment of Roger Dansey, M.D., to the company's Board of Directors. Dr. Dansey brings extensive experience in oncology drug development and a proven track record in the biotechnology industry. He currently serves as president, research and development of Seagen Inc. Dr. Dansey has dedicated his career to the development of innovative cancer therapies.

Prior to joining Seagen, Dr. Dansey held senior leadership roles at Merck, Gilead Sciences and Amgen. Dr. Dansey holds an M.D. from the University of Witwatersrand in Johannesburg, South Africa. He serves as a member of the board of directors for INOVIO Pharmaceuticals, Inc.